Aquestive Therapeutics reports Q1 results today with a notable insider selling cluster dominating the pre-earnings backdrop.
The insider signal is the sharpest data point heading in. Five executives — including the CEO, CFO, COO, and Chief Legal Officer — sold shares on May 5, just nine days before today's print. CEO Daniel Barber sold 335,922 shares at $4.18, netting roughly $1.4 million. The CFO and COO followed with combined proceeds of around $690,000. The cluster extended into May 7, when the CLO sold a further 135,690 shares. Net insider selling over the past 90 days totals approximately $4.9 million. That level of coordinated pre-earnings selling from the C-suite is unusual and hard to dismiss as routine.
Short interest adds texture to the setup rather than dominating it. Bears hold nearly 12.8% of the free float — a meaningful position that peaked closer to 14.5% in mid-April before retreating roughly 14% over the past month. Availability has tightened as lending demand picked back up this week, with the borrow rate running at 1.51%, up around 18% on the week. The ORTEX short score is elevated at 78.5, ranking in just the 4th percentile of the universe on short score — a reading that has climbed steadily over the past two weeks.
Options tell a more nuanced story. The put/call ratio has drifted higher to 0.41, above its 20-day average of 0.33, but the move is modest — less than one standard deviation above the mean and well below the 52-week high of 0.56. That positions options markets as incrementally more cautious than usual, but not alarmed. The stock itself has slipped about 2.4% on the week to $4.13, paring a 1.2% monthly gain.
The analyst backdrop is broadly positive but dated — the consensus has not been updated since early March, and the most recent target changes came from Piper Sandler and JMP Securities in late 2025, both raising targets toward the $8–$12 range. All covering firms carry positive ratings. The bull case centres on Anaphylm's regulatory trajectory and the no-needle epinephrine market opportunity; bears point to pipeline execution risk and balance sheet constraints that may require further capital raises. With the stock trading at $4.13 against a mean analyst target near $8.89, the gap is wide — though that target data is now several months old and should be read with some caution.
Today's print is less about whether AQST can show pipeline progress and more about whether management's own actions ahead of the release align with the optimistic regulatory story the Street has been buying.
See the live data behind this article on ORTEX.
Open AQST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
